AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
Identifieur interne : 001493 ( PubMed/Checkpoint ); précédent : 001492; suivant : 001494AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
Auteurs : Daniela Berg [Allemagne] ; Jana Godau ; Claudia Trenkwalder ; Karla Eggert ; Iiona Csoti ; Alexander Storch ; Heiko Huber ; Monica Morelli-Canelo ; Maria Stamelou ; Vincent Ries ; Martin Wolz ; Christine Schneider ; Thérèse Di Paolo ; Fabrizio Gasparini ; Sam Hariry ; Marc Vandemeulebroecke ; Walid Abi-Saab ; Katy Cooke ; Donald Johns ; Baltazar Gomez-MancillaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2011.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Drug Interactions, Dyskinesia, Drug-Induced (drug therapy), Excitatory Amino Acid Antagonists (administration & dosage), Excitatory Amino Acid Antagonists (adverse effects), Female, Follow-Up Studies, Humans, Levodopa (adverse effects), Male, Middle Aged, Parkinson Disease (drug therapy), Receptor, Metabotropic Glutamate 5, Receptors, Metabotropic Glutamate (antagonists & inhibitors), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Excitatory Amino Acid Antagonists.
- chemical , adverse effects : Antiparkinson Agents, Excitatory Amino Acid Antagonists, Levodopa.
- chemical , antagonists & inhibitors : Receptors, Metabotropic Glutamate.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Drug Interactions, Female, Follow-Up Studies, Humans, Male, Middle Aged, Receptor, Metabotropic Glutamate 5, Treatment Outcome.
Abstract
Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's disease patients with levodopa-induced dyskinesia. Two randomized, double-blind, placebo-controlled, parallel-group, in-patient studies for Parkinson's disease patients with moderate to severe levodopa-induced dyskinesia (study 1) and severe levodopa-induced dyskinesia (study 2) on stable dopaminergic therapy were performed. Patients received 25-150 mg AFQ056 or placebo twice daily for 16 days (both studies). Study 2 included a 4-day down-titration. Primary outcomes were the Lang-Fahn Activities of Daily Living Dyskinesia Scale (study 1), the modified Abnormal Involuntary Movement Scale (study 2), and the Unified Parkinson's Disease Rating Scale-part III (both studies). Secondary outcomes included the Unified Parkinson's Disease Rating Scale-part IV items 32-33. The primary analysis was change from baseline to day 16 on all outcomes. Treatment differences were assessed. Fifteen patients were randomized to AFQ056 and 16 to placebo in study 1; 14 patients were randomized to each group in study 2. AFQ056-treated patients showed significant improvements in dyskinesias on day 16 versus placebo (eg, Lang-Fahn Activities of Daily Living Dyskinesia Scale, P = .021 [study 1]; modified Abnormal Involuntary Movement Scale, P = .032 [study 2]). No significant changes were seen from baseline on day 16 on the Unified Parkinson's Disease Rating Scale-part III in either study. Adverse events were reported in both studies, including dizziness. Serious adverse events (most commonly worsening of dyskinesias, apparently associated with stopping treatment) were reported by 4 AFQ056-treated patients in study 1, and 3 patients (2 AFQ056-treated patient and 1 in the placebo group) in study 2. AFQ056 showed a clinically relevant and significant antidyskinetic effect without changing the antiparkinsonian effects of dopaminergic therapy. © 2011 Movement Disorder Society.
DOI: 10.1002/mds.23616
PubMed: 21484867
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:21484867Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.</title><author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name><affiliation wicri:level="3"><nlm:affiliation>University of Tübingen, Hertie-Institute of Clinical Brain Research and German Center for Neurodegenerative Diseases, Tübingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University of Tübingen, Hertie-Institute of Clinical Brain Research and German Center for Neurodegenerative Diseases, Tübingen</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Tübingen</settlement></placeName></affiliation></author><author><name sortKey="Godau, Jana" sort="Godau, Jana" uniqKey="Godau J" first="Jana" last="Godau">Jana Godau</name></author><author><name sortKey="Trenkwalder, Claudia" sort="Trenkwalder, Claudia" uniqKey="Trenkwalder C" first="Claudia" last="Trenkwalder">Claudia Trenkwalder</name></author><author><name sortKey="Eggert, Karla" sort="Eggert, Karla" uniqKey="Eggert K" first="Karla" last="Eggert">Karla Eggert</name></author><author><name sortKey="Csoti, Iiona" sort="Csoti, Iiona" uniqKey="Csoti I" first="Iiona" last="Csoti">Iiona Csoti</name></author><author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name></author><author><name sortKey="Huber, Heiko" sort="Huber, Heiko" uniqKey="Huber H" first="Heiko" last="Huber">Heiko Huber</name></author><author><name sortKey="Morelli Canelo, Monica" sort="Morelli Canelo, Monica" uniqKey="Morelli Canelo M" first="Monica" last="Morelli-Canelo">Monica Morelli-Canelo</name></author><author><name sortKey="Stamelou, Maria" sort="Stamelou, Maria" uniqKey="Stamelou M" first="Maria" last="Stamelou">Maria Stamelou</name></author><author><name sortKey="Ries, Vincent" sort="Ries, Vincent" uniqKey="Ries V" first="Vincent" last="Ries">Vincent Ries</name></author><author><name sortKey="Wolz, Martin" sort="Wolz, Martin" uniqKey="Wolz M" first="Martin" last="Wolz">Martin Wolz</name></author><author><name sortKey="Schneider, Christine" sort="Schneider, Christine" uniqKey="Schneider C" first="Christine" last="Schneider">Christine Schneider</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author><author><name sortKey="Gasparini, Fabrizio" sort="Gasparini, Fabrizio" uniqKey="Gasparini F" first="Fabrizio" last="Gasparini">Fabrizio Gasparini</name></author><author><name sortKey="Hariry, Sam" sort="Hariry, Sam" uniqKey="Hariry S" first="Sam" last="Hariry">Sam Hariry</name></author><author><name sortKey="Vandemeulebroecke, Marc" sort="Vandemeulebroecke, Marc" uniqKey="Vandemeulebroecke M" first="Marc" last="Vandemeulebroecke">Marc Vandemeulebroecke</name></author><author><name sortKey="Abi Saab, Walid" sort="Abi Saab, Walid" uniqKey="Abi Saab W" first="Walid" last="Abi-Saab">Walid Abi-Saab</name></author><author><name sortKey="Cooke, Katy" sort="Cooke, Katy" uniqKey="Cooke K" first="Katy" last="Cooke">Katy Cooke</name></author><author><name sortKey="Johns, Donald" sort="Johns, Donald" uniqKey="Johns D" first="Donald" last="Johns">Donald Johns</name></author><author><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="doi">10.1002/mds.23616</idno><idno type="RBID">pubmed:21484867</idno><idno type="pmid">21484867</idno><idno type="wicri:Area/PubMed/Corpus">001298</idno><idno type="wicri:Area/PubMed/Curation">001298</idno><idno type="wicri:Area/PubMed/Checkpoint">001493</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.</title><author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name><affiliation wicri:level="3"><nlm:affiliation>University of Tübingen, Hertie-Institute of Clinical Brain Research and German Center for Neurodegenerative Diseases, Tübingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University of Tübingen, Hertie-Institute of Clinical Brain Research and German Center for Neurodegenerative Diseases, Tübingen</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Tübingen</settlement></placeName></affiliation></author><author><name sortKey="Godau, Jana" sort="Godau, Jana" uniqKey="Godau J" first="Jana" last="Godau">Jana Godau</name></author><author><name sortKey="Trenkwalder, Claudia" sort="Trenkwalder, Claudia" uniqKey="Trenkwalder C" first="Claudia" last="Trenkwalder">Claudia Trenkwalder</name></author><author><name sortKey="Eggert, Karla" sort="Eggert, Karla" uniqKey="Eggert K" first="Karla" last="Eggert">Karla Eggert</name></author><author><name sortKey="Csoti, Iiona" sort="Csoti, Iiona" uniqKey="Csoti I" first="Iiona" last="Csoti">Iiona Csoti</name></author><author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name></author><author><name sortKey="Huber, Heiko" sort="Huber, Heiko" uniqKey="Huber H" first="Heiko" last="Huber">Heiko Huber</name></author><author><name sortKey="Morelli Canelo, Monica" sort="Morelli Canelo, Monica" uniqKey="Morelli Canelo M" first="Monica" last="Morelli-Canelo">Monica Morelli-Canelo</name></author><author><name sortKey="Stamelou, Maria" sort="Stamelou, Maria" uniqKey="Stamelou M" first="Maria" last="Stamelou">Maria Stamelou</name></author><author><name sortKey="Ries, Vincent" sort="Ries, Vincent" uniqKey="Ries V" first="Vincent" last="Ries">Vincent Ries</name></author><author><name sortKey="Wolz, Martin" sort="Wolz, Martin" uniqKey="Wolz M" first="Martin" last="Wolz">Martin Wolz</name></author><author><name sortKey="Schneider, Christine" sort="Schneider, Christine" uniqKey="Schneider C" first="Christine" last="Schneider">Christine Schneider</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author><author><name sortKey="Gasparini, Fabrizio" sort="Gasparini, Fabrizio" uniqKey="Gasparini F" first="Fabrizio" last="Gasparini">Fabrizio Gasparini</name></author><author><name sortKey="Hariry, Sam" sort="Hariry, Sam" uniqKey="Hariry S" first="Sam" last="Hariry">Sam Hariry</name></author><author><name sortKey="Vandemeulebroecke, Marc" sort="Vandemeulebroecke, Marc" uniqKey="Vandemeulebroecke M" first="Marc" last="Vandemeulebroecke">Marc Vandemeulebroecke</name></author><author><name sortKey="Abi Saab, Walid" sort="Abi Saab, Walid" uniqKey="Abi Saab W" first="Walid" last="Abi-Saab">Walid Abi-Saab</name></author><author><name sortKey="Cooke, Katy" sort="Cooke, Katy" uniqKey="Cooke K" first="Katy" last="Cooke">Katy Cooke</name></author><author><name sortKey="Johns, Donald" sort="Johns, Donald" uniqKey="Johns D" first="Donald" last="Johns">Donald Johns</name></author><author><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Drug Interactions</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Excitatory Amino Acid Antagonists (administration & dosage)</term><term>Excitatory Amino Acid Antagonists (adverse effects)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Receptor, Metabotropic Glutamate 5</term><term>Receptors, Metabotropic Glutamate (antagonists & inhibitors)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Excitatory Amino Acid Antagonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Excitatory Amino Acid Antagonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, Metabotropic Glutamate</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Drug Interactions</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Receptor, Metabotropic Glutamate 5</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's disease patients with levodopa-induced dyskinesia. Two randomized, double-blind, placebo-controlled, parallel-group, in-patient studies for Parkinson's disease patients with moderate to severe levodopa-induced dyskinesia (study 1) and severe levodopa-induced dyskinesia (study 2) on stable dopaminergic therapy were performed. Patients received 25-150 mg AFQ056 or placebo twice daily for 16 days (both studies). Study 2 included a 4-day down-titration. Primary outcomes were the Lang-Fahn Activities of Daily Living Dyskinesia Scale (study 1), the modified Abnormal Involuntary Movement Scale (study 2), and the Unified Parkinson's Disease Rating Scale-part III (both studies). Secondary outcomes included the Unified Parkinson's Disease Rating Scale-part IV items 32-33. The primary analysis was change from baseline to day 16 on all outcomes. Treatment differences were assessed. Fifteen patients were randomized to AFQ056 and 16 to placebo in study 1; 14 patients were randomized to each group in study 2. AFQ056-treated patients showed significant improvements in dyskinesias on day 16 versus placebo (eg, Lang-Fahn Activities of Daily Living Dyskinesia Scale, P = .021 [study 1]; modified Abnormal Involuntary Movement Scale, P = .032 [study 2]). No significant changes were seen from baseline on day 16 on the Unified Parkinson's Disease Rating Scale-part III in either study. Adverse events were reported in both studies, including dizziness. Serious adverse events (most commonly worsening of dyskinesias, apparently associated with stopping treatment) were reported by 4 AFQ056-treated patients in study 1, and 3 patients (2 AFQ056-treated patient and 1 in the placebo group) in study 2. AFQ056 showed a clinically relevant and significant antidyskinetic effect without changing the antiparkinsonian effects of dopaminergic therapy. © 2011 Movement Disorder Society.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21484867</PMID><DateCreated><Year>2011</Year><Month>06</Month><Day>21</Day></DateCreated><DateCompleted><Year>2011</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.</ArticleTitle><Pagination><MedlinePgn>1243-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.23616</ELocationID><Abstract><AbstractText>Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's disease patients with levodopa-induced dyskinesia. Two randomized, double-blind, placebo-controlled, parallel-group, in-patient studies for Parkinson's disease patients with moderate to severe levodopa-induced dyskinesia (study 1) and severe levodopa-induced dyskinesia (study 2) on stable dopaminergic therapy were performed. Patients received 25-150 mg AFQ056 or placebo twice daily for 16 days (both studies). Study 2 included a 4-day down-titration. Primary outcomes were the Lang-Fahn Activities of Daily Living Dyskinesia Scale (study 1), the modified Abnormal Involuntary Movement Scale (study 2), and the Unified Parkinson's Disease Rating Scale-part III (both studies). Secondary outcomes included the Unified Parkinson's Disease Rating Scale-part IV items 32-33. The primary analysis was change from baseline to day 16 on all outcomes. Treatment differences were assessed. Fifteen patients were randomized to AFQ056 and 16 to placebo in study 1; 14 patients were randomized to each group in study 2. AFQ056-treated patients showed significant improvements in dyskinesias on day 16 versus placebo (eg, Lang-Fahn Activities of Daily Living Dyskinesia Scale, P = .021 [study 1]; modified Abnormal Involuntary Movement Scale, P = .032 [study 2]). No significant changes were seen from baseline on day 16 on the Unified Parkinson's Disease Rating Scale-part III in either study. Adverse events were reported in both studies, including dizziness. Serious adverse events (most commonly worsening of dyskinesias, apparently associated with stopping treatment) were reported by 4 AFQ056-treated patients in study 1, and 3 patients (2 AFQ056-treated patient and 1 in the placebo group) in study 2. AFQ056 showed a clinically relevant and significant antidyskinetic effect without changing the antiparkinsonian effects of dopaminergic therapy. © 2011 Movement Disorder Society.</AbstractText><CopyrightInformation>Copyright © 2011 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Tübingen, Hertie-Institute of Clinical Brain Research and German Center for Neurodegenerative Diseases, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godau</LastName><ForeName>Jana</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Trenkwalder</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Eggert</LastName><ForeName>Karla</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Csoti</LastName><ForeName>Iiona</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Storch</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Heiko</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Morelli-Canelo</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Stamelou</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ries</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Wolz</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Thérèse</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Gasparini</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Hariry</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Vandemeulebroecke</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Abi-Saab</LastName><ForeName>Walid</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Cooke</LastName><ForeName>Katy</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Johns</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gomez-Mancilla</LastName><ForeName>Baltazar</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00582673</AccessionNumber><AccessionNumber>NCT00888004</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064529">Receptor, Metabotropic Glutamate 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018094">Receptors, Metabotropic Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018691">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D064529">Receptor, Metabotropic Glutamate 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018094">Receptors, Metabotropic Glutamate</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000037">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23616</ArticleId><ArticleId IdType="pubmed">21484867</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>Bade-Wurtemberg</li><li>District de Tübingen</li></region><settlement><li>Tübingen</li></settlement></list><tree><noCountry><name sortKey="Abi Saab, Walid" sort="Abi Saab, Walid" uniqKey="Abi Saab W" first="Walid" last="Abi-Saab">Walid Abi-Saab</name><name sortKey="Cooke, Katy" sort="Cooke, Katy" uniqKey="Cooke K" first="Katy" last="Cooke">Katy Cooke</name><name sortKey="Csoti, Iiona" sort="Csoti, Iiona" uniqKey="Csoti I" first="Iiona" last="Csoti">Iiona Csoti</name><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><name sortKey="Eggert, Karla" sort="Eggert, Karla" uniqKey="Eggert K" first="Karla" last="Eggert">Karla Eggert</name><name sortKey="Gasparini, Fabrizio" sort="Gasparini, Fabrizio" uniqKey="Gasparini F" first="Fabrizio" last="Gasparini">Fabrizio Gasparini</name><name sortKey="Godau, Jana" sort="Godau, Jana" uniqKey="Godau J" first="Jana" last="Godau">Jana Godau</name><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name><name sortKey="Hariry, Sam" sort="Hariry, Sam" uniqKey="Hariry S" first="Sam" last="Hariry">Sam Hariry</name><name sortKey="Huber, Heiko" sort="Huber, Heiko" uniqKey="Huber H" first="Heiko" last="Huber">Heiko Huber</name><name sortKey="Johns, Donald" sort="Johns, Donald" uniqKey="Johns D" first="Donald" last="Johns">Donald Johns</name><name sortKey="Morelli Canelo, Monica" sort="Morelli Canelo, Monica" uniqKey="Morelli Canelo M" first="Monica" last="Morelli-Canelo">Monica Morelli-Canelo</name><name sortKey="Ries, Vincent" sort="Ries, Vincent" uniqKey="Ries V" first="Vincent" last="Ries">Vincent Ries</name><name sortKey="Schneider, Christine" sort="Schneider, Christine" uniqKey="Schneider C" first="Christine" last="Schneider">Christine Schneider</name><name sortKey="Stamelou, Maria" sort="Stamelou, Maria" uniqKey="Stamelou M" first="Maria" last="Stamelou">Maria Stamelou</name><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name><name sortKey="Trenkwalder, Claudia" sort="Trenkwalder, Claudia" uniqKey="Trenkwalder C" first="Claudia" last="Trenkwalder">Claudia Trenkwalder</name><name sortKey="Vandemeulebroecke, Marc" sort="Vandemeulebroecke, Marc" uniqKey="Vandemeulebroecke M" first="Marc" last="Vandemeulebroecke">Marc Vandemeulebroecke</name><name sortKey="Wolz, Martin" sort="Wolz, Martin" uniqKey="Wolz M" first="Martin" last="Wolz">Martin Wolz</name></noCountry><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001493 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001493 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:21484867
|texte= AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:21484867" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |